In a phase 2 trial (about 218 people aged 65+), 6 weeks of low-dose everolimus raised flu vaccine response by about 20%. ConfidenceEstablished Level of evidence●●●●●○ Randomized clinical trial Observed inHuman MissionMap of aging (12 hallmarks) ConceptsDeregulated nutrient sensingRapamycin (and analogues: everolimus)mTOR (mTORC1)